Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are generally well enough to carry out daily activities with little or no limitation (a standard measure of physical fitness used in cancer care must be 0 or 1)
• People with an expected survival of at least 3 months
• People who have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed according to Chinese national liver cancer guidelines
• People whose cancer has not spread outside the liver, and whose cancer either cannot be removed by surgery or who have chosen not to have surgery
• People who have at least one clearly measurable tumour in the liver
• People whose tumours take up no more than 50% of the total liver volume
• People whose liver is functioning at an acceptable level (Child-Pugh score of 7 or below)
• People whose blood counts, liver function, kidney function, and blood clotting results all fall within the acceptable ranges required by the trial
• People of childbearing potential who agree to use effective contraception throughout the trial and for 6 months after it ends

Who may not be able to join:

• People who have previously had a condition where the liver stops filtering toxins properly, causing confusion or other brain symptoms (hepatic encephalopathy)
• People whose cancer has spread outside the liver, or who have another type of cancer
• People with a specific type of liver cancer that spreads through the liver tissue in a diffuse, infiltrating pattern rather than forming a distinct tumour
• People who have previously received any treatment for their liver cancer, including liver transplant, surgery, ablation, chemotherapy, radiation, targeted therapy, or immunotherapy
• People who have an abnormal structure in the liver's blood supply that would prevent certain procedures (TACE or SIRT) from being safely performed
• People who have a known allergy to contrast dyes or anaesthetic medications
• People with signs of serious complications related to liver disease, such as significant fluid build-up in the abdomen, severely swollen veins in the oesophagus or stomach, or advanced liver cirrhosis
• People with severely reduced lung function based on breathing test results
• People for whom the estimated radiation dose to a single lung would be too high (above 30 Gy)
• People who have a blood clot or tumour blocking major blood vessels connected to the liver, or blocking the bile duct
• People with a serious active infection that requires ongoing treatment
• People who are pregnant or breastfeeding
• People who test positive for HIV
• People with active hepatitis B virus (HBV) or hepatitis C virus (HCV) detected in the blood
• People with active syphilis or tuberculosis
• People who do not meet specific technical requirements on a pre-treatment imaging scan (a special nuclear medicine scan called 99mTc-MAA imaging), which checks whether the planned radiation treatment can be safely and effectively delivered (confirm with trial site for full technical details)

Important: Always verify eligibility with the trial site directly before applying.